Time New York: Tue 27 Sep 06:30 am  |  Save 15% on H&R Block Online


Becton, Dickinson (BDX) Introduces New Vascular Dressing


Leading global medical technology company, Becton, Dickinson and Company BDX or BD along with Avery Dennison Corporation AVY has introduced BD ChloraShield – a new line of transparent vascular dressings. The dressings have a chlorhexidine gluconate (CHG) antimicrobial preservative andare designed to enhance patient care. Moreover, the company believes that these dressings will be easy for clinicians to apply and remove. BD ChloraShield completes the company’sportfolio of a comprehensive set of products for vascular access procedures, including skin prep, catheters, connectors and flush products.

The new dressings feature BeneHold CHG, a propreitory adhesive technology from Avery Dennison. BeneHold CHG comfortably secures the dressing to the skin, absorb fluids and protects the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth, making it well-suited for catheter insertion sites. The Infusion Nurses Society’s recently released guidelines recommended the use of CHG dressings.

An innovative product pipeline is BD’s key growth driver. A vast array of regulatory approvals both in the U.S. and international markets are helping the company to rapidly expand its product portfolio. Moreover, the collaboration with Check-Points will drive demand for BD MAX assays that detect carbapenem-resistant organisms (CRO) in international markets. Both companies also plan to develop and commercialize a next-generation CRO assay for launch outside the U.S. in 2017 and later in the U.S.

The company is also in partnership with Central Admixture Pharmacy Services (CAPS). This will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.

We believe that these partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for full-year 2016 has remained steady at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.

Zacks Rank & Key Picks

Currently, BD carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector are Quidel Corp. QDEL and GW Pharmaceuticals plc GWPH. Notably, both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.